reference/20817333

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20817333

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Research Support, Non-U.S. Gov't
endingPage	3976
issn	0008-543X 1097-0142
issueIdentifier	16
pageRange	3968-3976
publicationName	Cancer
startingPage	3968
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f13172ccf7f819394f8961f07f52ba0f
bibliographicCitation	Bejanyan N, Tiu RV, Raza A, Jankowska A, Kalaycio M, Advani A, Chan J, Saunthararajah Y, Mooney L, Maciejewski JP, Sekeres MA. A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF). Cancer. 2012 Aug 15;118(16):3968–76. doi: 10.1002/cncr.26741. PMID: 22180010.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bdf58ec887de64dfdacc1a6a10cb1db8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16d24bda4c1d954b5ea83cba0757279f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7fe86343827646398567cfac867706d3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0376a793b79396b2540381a0b1b09725 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1261e76db945c3d4658ff4fffffeb0d9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e16064862efea936ad49e98e54a08ba http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1730f69f1bc2e00386bce870591eac3b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2a230357a12620b771e8886d4e51c490 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e6b5cc704f571f1632b058563455b0c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_afe98803dd1b003e23ae36f12df9245f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d3bda5b18f54bfad88901b99ac06994a
date	2011-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/cncr.26741 https://pubmed.ncbi.nlm.nih.gov/22180010
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771 https://portal.issn.org/resource/ISSN/0008-543X https://portal.issn.org/resource/ISSN/1097-0142
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF)
discusses	http://id.nlm.nih.gov/mesh/M0049263 http://id.nlm.nih.gov/mesh/M0015648 http://id.nlm.nih.gov/mesh/M0021267 http://id.nlm.nih.gov/mesh/M0001797 http://id.nlm.nih.gov/mesh/M0001724 http://id.nlm.nih.gov/mesh/M0006099
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D055728Q000188 http://id.nlm.nih.gov/mesh/D054437Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000077237 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D010087Q000008 http://id.nlm.nih.gov/mesh/D001152Q000008 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D003907Q000008 http://id.nlm.nih.gov/mesh/D013792Q000008 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D001205Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54670067 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11133 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9735 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5743 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID79143 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8561 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8560 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9285 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID14888 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9e97a47eb9e6c78b61149c74e7330d8f http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6287 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5426 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_54e32599939667ce8030f6c1725ceac0 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f1b19ffd977e0a98cd78708658634390

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129356432 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128423325 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127654813 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128458032

Total number of triples: 71.